These results suggest that antipsychotic exposure has no impact on relative mortality.
The use of atypical antipsychotics can be reduced with the implementation of a peer review prior authorization policy.
Type 2 diabetes is greater with second-generation antipsychotics than with non-second-generation antipsychotic psychotropic medications for patients aged 6 to 25 years.
The positive effects of antipsychotic medications in patients with schizophrenia and other psychotic disorders outweigh the adverse effects of antipsychotics on long-term outcomes.
The risk for rehospitalization was 22% lower during treatment with long-acting injectable antipsychotic medications compared with treatment with equivalent oral formulations in the total cohort.
Schizophrenia was perceived as more distressful and with higher perceived social stigma than other disorders.
Antipsychotic medications have potential toxic effects but delaying or withholding treatment can lead to worse outcomes.
Scientists researched the association between multiple drug treatments for psychotic disorders and anticholinergic burden.
Patients discharged with a mood stabilizer and an atypical antipsychotic had the lowest rehospitalization rate.
A trial at 3 mental health centers in The Netherlands revealed that patients with financial incentives have better compliance.
Adding high-dose B vitamins to traditional antipsychotic treatments reduces schizophrenia symptoms more than traditional treatments alone.
The risks of adverse events are similar with short-term use of typical and atypical antipsychotic medications after cardiac surgery in seniors.
There has been a sharp rise in the number of American seniors who take 3 or more medications that affect their central nervous system.
Both immediate and gradual discontinuation of the current antipsychotic medication are viable treatment options.
The use of antipsychotics was associated with an increased risk of acute respiratory failure in patients with chronic obstructive pulmonary disease (COPD).
The primary outcome in this study was the change in total quality-of-life scores from baseline to week 24 after patients were randomly assigned to a treatment group.
70% of severely mentally ill patients on Medicaid were not tested for diabetes, despite having a two to three times greater risk.
Guidelines, however, say that antipsychotics should only be used short term for severe psychotic symptoms and agitation.
PDP patients treated with antipsychotics were four times as likely to died following three to six months of treatment than those not on the meds.
Dementia patients who were younger, female and lived in nursing homes were most associated with psychotropic polypharmacy.
Rexulti (brexpiprazole), from Otsuka and Lundbeck, is approved as a monotherapy in schizophrenia and an adjunct in patients with major depression.
Almost 60% of people diagnosed with a first episode of psychosis were also smokers.
WHO identifies over 700 adverse event reports from Africa of patients taking what they thought was diazepam but was actually haloperidol.
Patients with late life schizophrenia who had their antipsychotic dose reduced had fewer side effects without sacrificing medication efficacy.
Males were more likely to be given antipsychotics than females, and among young adults given the drugs, depression was most common diagnosis.
Parkinson's patients who took any antipsychotic were more than twice as likely to die within 180 days than those not on one.
Invega Trinza is dosed once every four months following monthly treatment of Invega Sustenna for at least four months.
One psychiatrist is calling on authorities to declassify psychedelic drugs to study their therapeutic potential for mental illnesses.
Patients taking a long-acting injectable antipsychotic had better medication adherence and control of symptoms than peers taking a pill version.
In survey, patients with schizophrenia and psychiatrists both expressed displeasure over efficacy and side effects of current antipsychotics.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Cannabis Use in Adolescence Associated With Poorer Mental Health Outcomes
- Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia
- Minocycline vs Routine Care for Clinical Symptom Improvement in Schizophrenia
- Insomnia in Borderline Personality Disorder May Increase Suicide Risk
- FDA Approves Powerful New Opioid Despite Criticisms
- Heart Rate Variability Predicts Treatment Response in Anxious Depression
- Impulsivity in Bipolar Disorder, Borderline Personality Disorder, ADHD
- Psychotropic Medication May Reduce Symptoms and Improve Functioning in PTSD
- Social Decline a Predictor of Conversion Outcome in High-Risk Individuals
- Buprenorphine/Samidorphan Helpful in Refractory Depression